Avanos Medical (AVNS)
(Delayed Data from NYSE)
$18.10 USD
+0.25 (1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.09 -0.01 (-0.06%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth B Momentum B VGM
Income Statements
Fiscal Year end for AVANOS MEDICAL, INC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 673 | 820 | 745 | 715 | 698 |
Cost Of Goods | 294 | 370 | 380 | 342 | 295 |
Gross Profit | 380 | 450 | 364 | 373 | 402 |
Selling & Adminstrative & Depr. & Amort Expenses | 376 | 376 | 355 | 419 | 458 |
Income After Depreciation & Amortization | 4 | 74 | 9 | -46 | -56 |
Non-Operating Income | 3 | 1 | 0 | 1 | 7 |
Interest Expense | 15 | 10 | 3 | 16 | 15 |
Pretax Income | -8 | 65 | 6 | -61 | -64 |
Income Taxes | 2 | 15 | 1 | -33 | -18 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | 51 | 5 | -27 | -46 |
Extras & Discontinued Operations | -52 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | 51 | 5 | -27 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 50 | 122 | 47 | -3 | -19 |
Depreciation & Amortization (Cash Flow) | 46 | 48 | 38 | 43 | 37 |
Income After Depreciation & Amortization | 4 | 74 | 9 | -46 | -56 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 46.60 | 47.30 | 48.60 | 47.80 | 47.60 |
Diluted EPS Before Non-Recurring Items | 1.03 | 1.65 | 1.15 | 0.79 | 1.07 |
Diluted Net EPS (GAAP) | -1.32 | 1.07 | 0.11 | -0.57 | -0.96 |
Fiscal Year end for AVANOS MEDICAL, INC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 140.90 | 171.30 | 169.40 | 191.70 |
Cost Of Goods | NA | 59.00 | 75.80 | 71.60 | 87.20 |
Gross Profit | NA | 81.90 | 95.50 | 97.80 | 104.50 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 79.40 | 94.30 | 99.90 | 101.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.50 | 1.20 | -2.10 | 2.60 |
Non-Operating Income | NA | 1.00 | 0.90 | 0.50 | 0.50 |
Interest Expense | NA | 3.30 | 4.70 | 3.50 | 3.50 |
Pretax Income | NA | 0.20 | -2.60 | -5.10 | -0.40 |
Income Taxes | NA | -3.50 | 6.20 | -0.80 | 0.10 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 3.70 | -8.80 | -4.30 | -0.50 |
Extras & Discontinued Operations | NA | 6.80 | 5.10 | -63.80 | 0.00 |
Net Income (GAAP) | NA | 10.50 | -3.70 | -68.10 | -0.50 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 46.60 | 46.80 | 46.80 | 47.20 |
Diluted EPS Before Non-Recurring Items | NA | 0.36 | 0.30 | 0.24 | 0.27 |
Diluted Net EPS (GAAP) | NA | 0.23 | -0.08 | -1.46 | -0.01 |